MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Slēgts

32.59 1.4

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.75

Max

32.69

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 331M
Pārdošana	203M 3.2B
P/E Sektora vidējais	22.091 56.063
Dividenžu ienesīgums	2.48
Peļņas marža	10.368
Darbinieki	16,988
EBITDA	133M 856M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+8.77% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.48% 2.45%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.8B 13B
Iepriekšējā atvēršanas cena	31.19
Iepriekšējā slēgšanas cena	32.59

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. apr. 23:17 UTC

Peļņas

Samsung Forecasts Record First-Quarter Operating Profit

2026. g. 6. apr. 23:00 UTC

Karstas akcijas

Stocks to Watch: Health Insurers, Mawson, Owlet

2026. g. 6. apr. 22:13 UTC

Galvenie tirgus virzītāji

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026. g. 6. apr. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026. g. 6. apr. 17:09 UTC

Galvenie tirgus virzītāji

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026. g. 6. apr. 16:56 UTC

Galvenie ziņu notikumi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026. g. 6. apr. 14:47 UTC

Galvenie tirgus virzītāji

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026. g. 7. apr. 00:00 UTC

Galvenie ziņu notikumi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026. g. 6. apr. 23:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026. g. 6. apr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026. g. 6. apr. 23:36 UTC

Tirgus saruna

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026. g. 6. apr. 23:15 UTC

Tirgus saruna

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026. g. 6. apr. 22:14 UTC

Tirgus saruna

Correction to Live Cattle Futures Article

2026. g. 6. apr. 20:56 UTC

Tirgus saruna

Mexican Private Consumption Fell in January -- Market Talk

2026. g. 6. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 6. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026. g. 6. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026. g. 6. apr. 19:06 UTC

Tirgus saruna

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026. g. 6. apr. 18:36 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 17:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026. g. 6. apr. 17:13 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 16:33 UTC

Tirgus saruna

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026. g. 6. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. apr. 14:59 UTC

Peļņas

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

8.77% augšup

Prognoze 12 mēnešiem

Vidējais 34.96 USD 8.77%

Augstākais 35 USD

Zemākais 34.91 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.